A	B	C
1	Drugs
2		Brand	LY3002813
3		Generic	donanemab
4		MOA	N3pG mab (pyroglutamate modification), theorized to remove existing plaque. No affinity for any other AB form (!)
5		Indication	Early Symptomatic Alzheimer's Disease
6		Administration	IV
7
8			Phase II "TRAILBLAZER-ALZ" n=272 Early Symptomatic AD - NCT03367403, NEJM 2021
9			LY3202626 (BACE) also studied
10			iADRS -6.86 vs -10.06 for placebo, p=0.04 at 76 weeks
11			CDR-SB -0.36 (baseline 3.5), ADAS-COG13 -1.86 at 76 weeks (27.6 baseline)
12
13
14			Phase III "TRAILBLAZER-ALZ 2" n=1800 "Early AD" - NCT04437511
15			78-week study; prodromal AD, mild AD